Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedJun 28, 2026
DataAggregated Company Financials
Companies7
  • 7D7.1%
  • 3M9.4%
  • 1Y-3.1%
  • YTD3.8%

The Life Sciences industry is up 7.1% in the last week, with Lonza Group up 7.2%. Meanwhile, Xlife Sciences actually underperformed within the industry, shrinking 20% in the last week. In contrast, the industry has lost 3.1% in the last 12 months. Looking forward, earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 28 Jun 2026CHF 50.7bCHF 10.1bCHF 1.1b38.6x46.5x5x
Tue, 26 May 2026CHF 48.1bCHF 10.1bCHF 1.1b38.7x44.1x4.8x
Thu, 23 Apr 2026CHF 48.2bCHF 10.1bCHF 1.1b34.6x42.2x4.8x
Sat, 21 Mar 2026CHF 44.0bCHF 10.1bCHF 1.1b31.1x38.5x4.3x
Mon, 16 Feb 2026CHF 49.2bCHF 10.1bCHF 1.3b31.2x38.6x4.9x
Wed, 14 Jan 2026CHF 52.2bCHF 10.6bCHF 1.1b33.8x47.5x4.9x
Fri, 12 Dec 2025CHF 47.6bCHF 10.6bCHF 1.1b27.6x43.3x4.5x
Sun, 09 Nov 2025CHF 48.0bCHF 10.6bCHF 1.1b27.8x43.7x4.5x
Tue, 07 Oct 2025CHF 51.7bCHF 10.6bCHF 1.1b32.8x47x4.9x
Thu, 04 Sep 2025CHF 52.8bCHF 10.7bCHF 1.1b33.2x47.9x5x
Sat, 02 Aug 2025CHF 54.2bCHF 10.7bCHF 1.1b34.6x47.2x5.1x
Mon, 30 Jun 2025CHF 52.8bCHF 10.1bCHF 1.0b33.6x50.8x5.2x
Wed, 28 May 2025CHF 52.8bCHF 10.1bCHF 1.0b32x50.8x5.2x
Fri, 25 Apr 2025CHF 51.8bCHF 10.1bCHF 1.0b29.2x50.5x5.1x
Sun, 23 Mar 2025CHF 53.6bCHF 10.1bCHF 1.0b33.1x52.6x5.3x
Tue, 18 Feb 2025CHF 57.7bCHF 10.1bCHF 1.0b36.8x57.4x5.7x
Thu, 16 Jan 2025CHF 53.3bCHF 10.2bCHF 943.4m34.8x56.5x5.2x
Sat, 14 Dec 2024CHF 53.1bCHF 10.2bCHF 943.5m38.6x56.3x5.2x
Mon, 11 Nov 2024CHF 55.9bCHF 10.2bCHF 943.4m43.8x59.2x5.5x
Wed, 09 Oct 2024CHF 54.4bCHF 10.2bCHF 943.3m41.3x57.6x5.3x
Fri, 06 Sep 2024CHF 55.5bCHF 10.2bCHF 937.1m43.3x59.3x5.4x
Sun, 04 Aug 2024CHF 57.4bCHF 10.2bCHF 924.3m44.5x62.1x5.6x
Tue, 02 Jul 2024CHF 51.2bCHF 10.3bCHF 1.0b44.1x51.1x5x
Thu, 30 May 2024CHF 51.8bCHF 10.3bCHF 1.0b43.3x51.8x5x
Sat, 27 Apr 2024CHF 55.2bCHF 10.3bCHF 1.0b43.8x55.1x5.4x
Mon, 25 Mar 2024CHF 57.2bCHF 10.2bCHF 1.0b45.9x56.9x5.6x
Wed, 21 Feb 2024CHF 49.4bCHF 10.2bCHF 1.0b45.4x48.5x4.9x
Fri, 19 Jan 2024CHF 41.5bCHF 9.8bCHF 1.5b31.2x27.8x4.3x
Sun, 17 Dec 2023CHF 41.2bCHF 9.8bCHF 1.5b32.6x27.6x4.2x
Tue, 14 Nov 2023CHF 39.4bCHF 9.8bCHF 1.5b27.1x26.4x4x
Thu, 12 Oct 2023CHF 47.1bCHF 9.8bCHF 1.5b32x31.5x4.8x
Sat, 09 Sep 2023CHF 51.9bCHF 9.8bCHF 1.5b35.7x34.8x5.3x
Mon, 07 Aug 2023CHF 52.9bCHF 9.8bCHF 1.5b35.3x34.2x5.4x
Wed, 05 Jul 2023CHF 55.2bCHF 9.7bCHF 1.6b36.1x33.8x5.7x
Price to Earnings Ratio

33.8x


Total Market Cap: CHF 55.2bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 46.5x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 13% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market2.22%
Healthcare5.29%
Life Sciences7.07%
Clinical Research and Equipment7.07%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 534.607.2%
+CHF 2.5b		-5.6%PE41.1x
BANB Bachem HoldingCHF 71.905.8%
+CHF 296.0m		21.9%PE36.2x
PPGN PolyPeptide GroupCHF 46.5018.2%
+CHF 236.0m		127.9%PS4.3x
TECN Tecan GroupCHF 162.607.2%
+CHF 136.6m		0.6%PS2.3x
SKAN SKAN GroupCHF 54.3010.1%
+CHF 112.4m		-23.9%PE75x

Latest News

PPGN
CHF 46.50
PolyPeptide Group
7D
18.2%
1Y
127.9%
Narrative Update • Jun 26

PPGN: Raised Price Views Will Likely Overstate Takeover Hopes

Analysts have lifted their price target on PolyPeptide Group to a range around CHF 38 to CHF 40 from prior levels near CHF 33 to CHF 35. This change reflects updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples.
LONN
CHF 534.60
Lonza Group
7D
7.2%
1Y
-5.6%
BANB
CHF 71.90
Bachem Holding
7D
5.8%
1Y
21.9%
Narrative Update • Jun 22

BANB: Capacity Expansion Commitments Will Heighten Execution Risk And Restrain Upside

Analysts have raised their price target on Bachem Holding by CHF 5 to reflect updated assumptions for discount rates, growth and profitability. This move is supported by recent Street research that cites a higher target from CHF 5 at Barclays as a reference point for the new CHF level.
SFZN
CHF 70.00
Siegfried Holding
7D
3.0%
1Y
-21.4%
Analysis Article • Jun 19

Siegfried Holding (SWX:SFZN) Stock Could Be 35.5% Undervalued After New API Facility Opens

Siegfried Holding (SWX:SFZN) has opened a new large scale API manufacturing facility in Minden, Germany, adding 100 m³ of reactor capacity and expanding its role as a global CDMO for small molecule drug substances. See our latest analysis for Siegfried Holding. Despite Siegfried Holding’s new API facility pointing to expanded capacity and customer demand, recent momentum has been weak, with the share price down 16.82% over 30 days and the 1 year total shareholder return down 28.36%,...
SKAN
CHF 54.30
SKAN Group
7D
10.1%
1Y
-23.9%
Narrative Update • Jun 17

SKAN: Dividend Payouts And Order Backlog Will Support Future Returns

Analysts have kept their SKAN Group price target steady at CHF 62.50, noting that small adjustments to the discount rate and future P/E assumptions did not materially change their overall valuation view. What’s in the News for SKAN Group The Board of Directors of SKAN Group AG plans to propose a dividend of CHF 0.22 per share to the Annual General Meeting on May 7, 2026, corresponding to a 30% payout ratio.
TECN
CHF 162.60
Tecan Group
7D
7.2%
1Y
0.6%
Narrative Update • Jun 14

TECN: Reset CHF 205 Goal Will Support Future Earnings Re Rating

Analysts have reduced their price target for Tecan Group from CHF 335.08 to CHF 205.00, citing updated assumptions for revenue growth, profit margins and future P/E multiples, along with recent Street research cuts from CHF 10 and CHF 1. Analyst Commentary Recent Street research has focused on recalibrating Tecan Group’s valuation framework, with price targets adjusted to reflect updated views on revenue growth, margins and P/E multiples.
XLS
CHF 20.20
Xlife Sciences
7D
-19.8%
1Y
2.3%